Genor Biopharma Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2007-12-04
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genorbio.com
A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT06934616
A Study of [14C]GB491 in Male Healthy Subjects
- Conditions
- Nonsmall Cell Lung CancerBreast Cancer
- Interventions
- Drug: [14C]GB491
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05860582
- Locations
- 🇨🇳
Beijing GoBroad Boren Hospital, Beijing, Beijing, China
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT05851014
- Locations
- 🇨🇳
Xingtai People's Hospital, Xingtai, Hebei, China
🇨🇳Hubei Cancer Hospital, Wuhan, Hubei, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- Drug: GB491+Letrozole
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT05337657
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor
- Conditions
- NSCLCOther Solid Tumors
- Interventions
- Biological: GB263T
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05332574
- Locations
- 🇦🇺
Genesis Care, Saint Leonards, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- Drug: Placebo+Fulvestrant
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 275
- Registration Number
- NCT05054751
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.
- Conditions
- B Cell NHLCLL
- Interventions
- Biological: GB261
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 460
- Registration Number
- NCT04923048
- Locations
- 🇦🇺
One Clinical Research Pty Ltd, Mount Pleasant, Western Australia, Australia
🇦🇺St Vincent's Hospital/The Kinghorn Cancer Centre, Sydney, New South Wales, Australia
🇦🇺Cabrini hospital, Melbourne, The State Of Victoria, Australia
Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 87
- Registration Number
- NCT04905667
- Locations
- 🇨🇳
The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangzhou, China
A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis Patients
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: GB224 10mgBiological: GB224 20mg
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04179513
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Phase â… Clinical Trial of Gerilimzumab Injection in Healthy Subjects
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: Placebo, 10mgOther: Placebo, 20mgBiological: GB224 15mgBiological: GB224 30mgBiological: GB224 10mgOther: Placebo, 2mgOther: Placebo, 5mgBiological: GB224 2mgBiological: GB224 5mgBiological: GB224 20mgOther: Placebo, 15mgOther: Placebo, 30mg
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT04178070
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China